$BMRN
BIOMARIN PHARMACEUTICAL INC

2019 Q4 Form 10-Q Financial Statement

#000104847719000015 Filed on October 29, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $454.4M $461.1M $387.8M
YoY Change 28.65% 17.72% 4.0%
Cost Of Revenue $95.90M $96.95M $77.44M
YoY Change 27.87% 22.89% -2.0%
Gross Profit $358.5M $364.1M $310.3M
YoY Change 28.86% 16.41% 5.62%
Gross Profit Margin 78.9% 78.97% 80.03%
Selling, General & Admin $187.8M $170.1M $160.8M
YoY Change 11.32% 14.5% 4.88%
% of Gross Profit 52.38% 46.72% 51.8%
Research & Development $172.8M $173.0M $185.6M
YoY Change -1.48% 7.16% 5.73%
% of Gross Profit 48.2% 47.5% 59.82%
Depreciation & Amortization $25.80M $24.24M $21.53M
YoY Change 4.45% -8.88% 7.11%
% of Gross Profit 7.2% 6.66% 6.94%
Operating Expenses $376.9M $343.1M $346.4M
YoY Change 7.17% 10.68% 5.33%
Operating Profit -$18.40M $4.010M -$41.35M
YoY Change -74.97% -125.47% 63.69%
Interest Expense -$2.300M $2.937M $6.866M
YoY Change -171.88% -75.79% -43.84%
% of Operating Profit 73.24%
Other Income/Expense, Net $900.0K $4.000M $500.0K
YoY Change -129.03% 53.85% -82.14%
Pretax Income -$9.800M $9.822M -$41.90M
YoY Change -77.37% -150.59% 43.59%
Income Tax -$24.80M -$45.21M -$4.460M
% Of Pretax Income -460.33%
Net Earnings $15.00M $55.04M -$37.44M
YoY Change -505.41% -536.1% 122.93%
Net Earnings / Revenue 3.3% 11.94% -9.65%
Basic Earnings Per Share $0.31 -$0.21
Diluted Earnings Per Share $83.57K $0.30 -$0.21
COMMON SHARES
Basic Shares Outstanding 179.6M shares 179.3M shares 179.0M shares
Diluted Shares Outstanding 185.9M shares 179.0M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $753.8M $720.8M $731.1M
YoY Change -30.48% -50.06% -46.36%
Cash & Equivalents $437.4M $423.2M $307.6M
Short-Term Investments $316.4M $297.6M $423.5M
Other Short-Term Assets $130.7M $126.5M $119.8M
YoY Change 32.78% 76.5% 49.54%
Inventory $680.3M $609.0M $578.7M
Prepaid Expenses
Receivables $377.4M $403.0M $377.2M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.942B $1.859B $1.807B
YoY Change -5.55% -22.78% -20.76%
LONG-TERM ASSETS
Property, Plant & Equipment $1.011B $969.3M $963.0M
YoY Change 6.55% 4.9% 6.94%
Goodwill $197.0M $197.0M $197.0M
YoY Change 0.0%
Intangibles $456.6M $462.8M $476.6M
YoY Change -7.16%
Long-Term Investments $412.0M $431.8M $375.0M
YoY Change 74.65% 110.74% 33.93%
Other Assets $122.0M $112.6M $99.46M
YoY Change 233.65% -75.87% -78.6%
Total Long-Term Assets $2.748B $2.699B $2.587B
YoY Change 15.9% 17.98% 10.32%
TOTAL ASSETS
Total Short-Term Assets $1.942B $1.859B $1.807B
Total Long-Term Assets $2.748B $2.699B $2.587B
Total Assets $4.690B $4.558B $4.393B
YoY Change 5.94% -2.92% -5.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $241.0M $233.5M $223.9M
YoY Change 15.81% 29.29% 33.27%
Accrued Expenses $287.9M $223.2M $180.6M
YoY Change 35.16% 26.75% 8.01%
Deferred Revenue $13.04M
YoY Change 788.68%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $365.1M $3.000M $2.900M
YoY Change -99.2% -99.22%
Total Short-Term Liabilities $932.5M $493.7M $439.4M
YoY Change 78.22% -41.13% -45.41%
LONG-TERM LIABILITIES
Long-Term Debt $492.9M $853.2M $847.1M
YoY Change -40.64% 3.28% 3.07%
Other Long-Term Liabilities $98.12M $97.43M $103.7M
YoY Change 67.31% -15.64% -8.08%
Total Long-Term Liabilities $98.12M $97.43M $103.7M
YoY Change 67.31% -89.65% -88.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $932.5M $493.7M $439.4M
Total Long-Term Liabilities $98.12M $97.43M $103.7M
Total Liabilities $1.568B $1.484B $1.432B
YoY Change 7.43% -16.66% -17.66%
SHAREHOLDERS EQUITY
Retained Earnings -$1.721B -$1.736B -$1.791B
YoY Change 1.57%
Common Stock $4.833B $4.783B $4.744B
YoY Change 3.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.122B $3.074B $2.961B
YoY Change
Total Liabilities & Shareholders Equity $4.690B $4.558B $4.393B
YoY Change 5.94% -2.92% -5.0%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $15.00M $55.04M -$37.44M
YoY Change -505.41% -536.1% 122.93%
Depreciation, Depletion And Amortization $25.80M $24.24M $21.53M
YoY Change 4.45% -8.88% 7.11%
Cash From Operating Activities $57.40M $70.10M -$24.30M
YoY Change 16.19% 48.52% -28.32%
INVESTING ACTIVITIES
Capital Expenditures -$60.80M -$35.40M -$38.40M
YoY Change 44.42% -28.92% 70.67%
Acquisitions
YoY Change
Other Investing Activities $12.00M $84.10M $58.00M
YoY Change -141.52% -81.4% 112.45%
Cash From Investing Activities -$48.90M $48.70M $19.70M
YoY Change -31.03% -87.89% 319.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000M -2.000M -51.70M
YoY Change -101.09% -138.46% 204.12%
NET CHANGE
Cash From Operating Activities 57.40M 70.10M -24.30M
Cash From Investing Activities -48.90M 48.70M 19.70M
Cash From Financing Activities 4.000M -2.000M -51.70M
Net Change In Cash 12.50M 116.8M -56.30M
YoY Change -103.22% -74.31% 21.86%
FREE CASH FLOW
Cash From Operating Activities $57.40M $70.10M -$24.30M
Capital Expenditures -$60.80M -$35.40M -$38.40M
Free Cash Flow $118.2M $105.5M $14.10M
YoY Change 29.18% 8.76% -223.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
178252954 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
179604381 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
178252954 shares
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
179604381 shares
CY2019Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-26727
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493982000 USD
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
179625303 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
423220000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
297572000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
590326000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
402970000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
342633000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
609049000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
530871000 USD
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
126548000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
98403000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
1859359000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
2056215000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
431804000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
235864000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
969300000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
948682000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
462849000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
491808000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
197039000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
197039000 USD
CY2019Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
525131000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
460952000 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112646000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36568000 USD
CY2019Q3 us-gaap Liabilities
Liabilities
1483723000 USD
CY2019Q3 us-gaap Assets
Assets
4558128000 USD
CY2018Q4 us-gaap Assets
Assets
4427128000 USD
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
483745000 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
437290000 USD
CY2019Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
10000000 USD
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
85951000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
493745000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
523241000 USD
CY2019Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
843616000 USD
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
830417000 USD
CY2019Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
48930000 USD
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
46883000 USD
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
97432000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
58647000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
1459188000 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
180000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
178000 USD
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4782916000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4669926000 USD
CY2019Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9961000 USD
CY2018Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
13301000 USD
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
37003000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5271000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1735733000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1694134000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3074405000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2967940000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4558128000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4427128000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461097000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
391706000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1249605000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1137998000 USD
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
96949000 USD
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
78893000 USD
us-gaap Cost Of Revenue
CostOfRevenue
263567000 USD
us-gaap Cost Of Revenue
CostOfRevenue
240245000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172963000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
161408000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
542195000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
440182000 USD
CY2019Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17063000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
520938000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
170112000 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
148566000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
493024000 USD
CY2018Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
18580000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17537000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17141000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
57114000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
42009000 USD
CY2019Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2018Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
15000000 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
20000000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
457087000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
407447000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1340900000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1223374000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
4010000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15741000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-91295000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-85376000 USD
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-551000 USD
CY2018Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-468000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-780000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-507000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5340000 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6338000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
2937000 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
12131000 USD
us-gaap Interest Expense
InterestExpense
16530000 USD
us-gaap Interest Expense
InterestExpense
35918000 USD
CY2019Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3960000 USD
CY2018Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2589000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
6038000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
5266000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9822000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19413000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-85030000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-99394000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45214000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6793000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-46158000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-25833000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
55036000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12620000 USD
us-gaap Net Income Loss
NetIncomeLoss
-38872000 USD
us-gaap Net Income Loss
NetIncomeLoss
-73561000 USD
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3074405000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2914945000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9395000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
26099000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1897000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-769000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3074405000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2914945000 USD
us-gaap Net Income Loss
NetIncomeLoss
-38872000 USD
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179289000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177481000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178873000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
176767000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185924000 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177481000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178873000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
176767000 shares
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74600000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13651000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7140000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52174000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2960954000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2885104000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2967940000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2808663000 USD
us-gaap Net Income Loss
NetIncomeLoss
-73561000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79510000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
70955000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
121763000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
112261000 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
15000000 USD
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
20000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-59780000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-32735000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-784000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
11997000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5646000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
12836000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
459000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
439198000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61803000 USD
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
15000000 USD
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
20000000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8323000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1747000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
10000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
95884000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
52571000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10232000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
13259000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4276000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7112000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3148000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21747000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12090000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2386000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3744000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9081000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29166000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94241000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
102541000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
635678000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
857063000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
528497000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17870000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
335314000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21768000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
55643000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40951000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
34180000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
57508000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
43108000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2025000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-78716000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-21645000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-835000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-347000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-70762000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
284156000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493982000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
598028000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
423220000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
882184000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
6088000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
15791000 USD
us-gaap Interest Paid Net
InterestPaidNet
5777000 USD
us-gaap Interest Paid Net
InterestPaidNet
7521000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-5801000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-7678000 USD
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF OPERATIONS<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
BASIS OF PRESENTATION<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K. The results of operations for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> are not necessarily indicative of the results that may be expected for the fiscal year ending </span><span style="font-family:Arial;font-size:9pt;">December 31, 2019</span><span style="font-family:Arial;font-size:9pt;"> or any other period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;"> (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;">. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of </span><span style="font-family:Arial;font-size:9pt;"><span>$55.9 million</span></span><span style="font-family:Arial;font-size:9pt;"> and lease liabilities of </span><span style="font-family:Arial;font-size:9pt;"><span>$59.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="font-family:Arial;font-size:9pt;"> (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
431804000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1322661000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1147834000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4928000 USD
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
165000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1152596000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
423220000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
297572000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
497000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2986000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1320172000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493982000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
590326000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
235864000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
642677000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
307995000 USD
CY2019Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 USD
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
326359000 USD
CY2019Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
642677000 USD
CY2018Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
634354000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
179828000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
142546000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
462849000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
491808000 USD
CY2019Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
15000000.0 USD
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1504909000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1421317000 USD
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
535609000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
472635000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
969300000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
948682000 USD
CY2019Q3 us-gaap Depreciation
Depreciation
24200000 USD
us-gaap Depreciation
Depreciation
67200000 USD
CY2019Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
9800000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
24900000 USD
CY2018Q3 us-gaap Depreciation
Depreciation
26600000 USD
us-gaap Depreciation
Depreciation
66700000 USD
CY2018Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
8100000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
18600000 USD
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
68391000 USD
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74616000 USD
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
321073000 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
231064000 USD
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
219585000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
225191000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
609049000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
530871000 USD
CY2019Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
226769000 USD
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
207620000 USD
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
132049000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
149937000 USD
CY2019Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
55957000 USD
CY2018Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
43116000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8721000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
2865000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
11586000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8406000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
2258000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
10664000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
7504000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
1748000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1340900000 USD
CY2019Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
27881000 USD
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
19977000 USD
CY2019Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7556000 USD
CY2018Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7785000 USD
CY2019Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8731000 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4178000 USD
CY2019Q3 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
10225000 USD
CY2018Q4 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
0 USD
CY2019Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
14577000 USD
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4677000 USD
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
483745000 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
437290000 USD
CY2019Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
52863000 USD
CY2018Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
23178000 USD
CY2019Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
16374000 USD
CY2018Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
7831000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
457087000 USD
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
19200000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51284000 USD
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
10346000 USD
CY2019Q3 bmrn Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
61630000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7273000 USD
CY2019Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2952000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45499000 USD
CY2019Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
9544000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
65268000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3115000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
3204000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
6319000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9925000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
3464000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
13389000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due Year Five
OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive
9252000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
27464000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due After Year Five
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive
27464000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
65135000 USD
CY2019Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
13539000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
78674000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12363000 USD
CY2019Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1043000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
13406000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
52772000 USD
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
12496000 USD
CY2019Q3 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
65268000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
4277000 USD
us-gaap Lease Cost
LeaseCost
12212000 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2019Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.054
CY2019Q3 bmrn Lessee Operating Lease Lease Notyet Commenced Liability
LesseeOperatingLeaseLeaseNotyetCommencedLiability
0 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5918000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
454000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2027000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9268000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
72000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
12976000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
12549000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
11198000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
10574000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
9993000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
27701000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
84991000 USD
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
12200000 USD
CY2018Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2100000 USD
CY2018Q4 us-gaap Deferred Rent Asset Net Current
DeferredRentAssetNetCurrent
500000 USD
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
870000000.0 USD
CY2019Q3 us-gaap Convertible Debt
ConvertibleDebt
843616000 USD
CY2018Q4 us-gaap Convertible Debt
ConvertibleDebt
830417000 USD
CY2019Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
875010000 USD
CY2018Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
911348000 USD
CY2019Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
24492000 USD
CY2019Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
4808000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
120000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19564000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
42684000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
9286000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1666000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31732000 USD
CY2018Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
4830000 USD
CY2018Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
5523000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
338000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1031000 USD
CY2017Q4 bmrn Stockholders Equity Adjusted Balance
StockholdersEquityAdjustedBalance
-23547000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
226000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
18692000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-2921000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29600000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
21387000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461097000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
391706000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1249605000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1137998000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
14300000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39173000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37046000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121763000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112261000 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5100000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
13200000 USD
CY2018Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5300000 USD
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
107473 shares
CY2019Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-45200000 USD
CY2019Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-27100000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
55036000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12620000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38872000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73561000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
55973000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12620000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38872000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-73561000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179289000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177481000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178873000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
176767000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185924000 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177481000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178873000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
176767000 shares
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13394000 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23479000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20028000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23479000 shares
bmrn Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
376900000 USD
CY2019Q3 bmrn Contingent Liability Accrual Sales And Licensing Milestones
ContingentLiabilityAccrualSalesAndLicensingMilestones
69100000 USD
CY2019Q3 bmrn Contingent Liability Accrual Sales And Licensing Milestones Current
ContingentLiabilityAccrualSalesAndLicensingMilestonesCurrent
20200000 USD

Files In Submission

Name View Source Status
0001048477-19-000015-index-headers.html Edgar Link pending
0001048477-19-000015-index.html Edgar Link pending
0001048477-19-000015.txt Edgar Link pending
0001048477-19-000015-xbrl.zip Edgar Link pending
bmrn-20190930.xsd Edgar Link pending
bmrn-20190930_cal.xml Edgar Link unprocessable
bmrn-20190930_def.xml Edgar Link unprocessable
bmrn-20190930_lab.xml Edgar Link unprocessable
bmrn-20190930_pre.xml Edgar Link unprocessable
bmrn-30sep19x10q.htm Edgar Link pending
bmrn-30sep19x10q_htm.xml Edgar Link completed
exhibit101-30sep19x10q.htm Edgar Link pending
exhibit311-30sep19x10q.htm Edgar Link pending
exhibit312-30sep19x10q.htm Edgar Link pending
exhibit321-30sep19x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending